Program
MK4646
A development code. Also written as “MK-4646”.
Its studies are mostly in HIV Infections, led by Merck.
Furthest: phase 1, since Jun 9, 20254 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 41 open or running | phase 1since Jun 9, 2025 | Jun 9, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 9, 2025First study: phase 1 study in HIV InfectionsFirst studyNCT07042945 · 15 enrolled · Moldova, Romania
- Sep 22, 2025Phase 1 study in HealthyNCT07199452 · 18 enrolled · United States
- Apr 8, 2026Phase 1 study in HealthyNCT07532304 · 16 enrolled · United States
- Aug 21, 2026Phase 1 study in HealthyNCT07785830 · 16 enrolled · United States
Ahead
- Nov 10, 2026Primary completion: phase 1 study in HealthyNCT07785830
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07785830Healthy · United States | 1 | Active, not recruiting | Nov 10, 2026 | 16 |
| NCT07532304Healthy · United States | 1 | Completed | Jul 23, 2026 | 16 |
| NCT07199452Healthy · United States | 1 | Completed | Dec 27, 2025 | 18 |
| NCT07042945HIV Infections · Moldova, Romania | 1 | Completed | Jun 5, 2026 | 15 |
How it is read
Names in the registry
- “MK-4646”, 3 entries
- “MK4646”, 1 entry
Codes read as this program: MK4646.
Conditions, from the studies’ own filings
- HIV Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.